Oruka Therapeutics, Inc. ORKA
107.17 USD -2.33 (-2.13%)
At closeNov 11, 2026, 5:04 PM EST
106.02 -1.15 -1.07%
After hours · Nov 11, 5:04 PM ET
106.26 Day range 112.42
25.23 52-week range 115.52
- YTD
- +253.58%
- 1 year
- +280.04%
News
benzinga.com Oruka Therapeutics Q3 EPS $(0.63) Misses $(0.60) Estimate Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.60) by 5 percent. This is a 14.55 percent decrease over losses of…
globenewswire.com Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-B Week 16 results showed 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose group, highly consistent with EVERLAST-A
defenseworld.net Oruka Therapeutics, Inc. $ORKA Stock: Candriam S.C.A. Lowers Holdings Candriam S.C.A. trimmed its holdings in Oruka Therapeutics, Inc. (NASDAQ: ORKA) by 3.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission.…
benzinga.com Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
benzinga.com Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
benzinga.com Oruka Therapeutics Novel Biologic Outperforms Placebo in Psoriasis Trial Oruka Therapeutics reported positive Week 16 Phase 2b data for ORKA-001, showing 61% complete skin clearance in plaque psoriasis patients.
benzinga.com Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday U.S. stocks rose; Dow gained 350 points. Range Resources jumped 15% on EQT acquisition, while Surgery Partners and others posted sharp gains.- benzinga.com Oruka Reports Week 16 Phase 2b Results For ORKA-001 In Plaque Psoriasis, With 61% PASI 100 And 86% PASI 90 Response Rates; ORKA-001 On Track To Advance Into Phase 3 Trials In 1H 2027 61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-AContinued favorable safety and tolerability profile consistent with the IL-23p19 classORKA-001 on…
benzinga.com BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
benzinga.com Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.- benzinga.com HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy Oruka Therapeutics reports positive week 28 results from its Phase 2a trial for plaque psoriasis treatment ORKA-001.- benzinga.com Oruka Therapeutics Announces Week 28 Results From Its EVERLAST-A Phase 2A Trial Of ORKA-001 In Moderate-To-Severe Plaque Psoriasis; ORKA-001 Maintained Favorable Safety And Tolerability Profile Through Week 28; 16-Week EVERLAST-B Data Expected In Q4 2026 Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis."These Week 28 results, with responses…
benzinga.com HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.- benzinga.com Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
- benzinga.com BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
- benzinga.com Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) Estimate Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of…
benzinga.com HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
benzinga.com BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
benzinga.com Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares Oruka Therapeutics stock falls after hours after Fairmount sells a $300 million stake via SEC filing.- benzinga.com UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130 UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $100 to $130.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
benzinga.com Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC,…- benzinga.com Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Paragon Amendment On May 29, 2026, Oruka Therapeutics, Inc. (the "Company") entered into the First Amendment to IL-23 License Agreement (the "Amendment"), amending the IL-23 License Agreement dated as of December 17,…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $120 price target.
- benzinga.com BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target BTIG analyst Julian Harrison reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $151 price target.
- benzinga.com Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent. This is a 20 percent decrease over losses of…
- benzinga.com Oruka Therapeutics Files Prospectus For Offering 9.66M Common Shares https://www.sec.gov/Archives/edgar/data/907654/000121390026049372/ea0288174-424b5_oruka.htm
- benzinga.com HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $120 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $120.
benzinga.com CommVault, Kforce, AxoGen And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimates. Other gainers include Kforce, Omnicell, and AxoGen.- benzinga.com UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $100 UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $100.
- benzinga.com Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $160 Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and raises the price target from $78 to $160.
- benzinga.com Oruka Therapeutics Launches $500M Public Offering Oruka Therapeutics, Inc. (NASDAQ:ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology…
- benzinga.com BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $151 BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $78 to $151.
benzinga.com Oruka Therapeutics Stock Explodes As Psoriasis Data Shows 'Highly Compelling' Skin Clearance Oruka Therapeutics shares rise as ORKA-001 shows strong psoriasis clearance rates and durable dosing potential in Phase 2a EVERLAST-A trial.
benzinga.com XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY,…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com Oruka Therapeutics Announces Interim Results From EVERLAST-A Phase 2a Trial Of ORKA-001, Half-Life Extended IL-23p19 Monoclonal Antibody, In Moderate-To-Severe Plaque Psoriasis ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16Favorable safety profile consistent with the IL-23p19 classUpdated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with…
benzinga.com Microsoft To $500? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and upgrades/downgrades on our analyst ratings page.
benzinga.com Wedbush Maintains Outperform on Oruka Therapeutics, Raises Price Target to $85 Wedbush analyst Martin Fan maintains Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and raises the price target from $45 to $85.- benzinga.com Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $125 Price Target Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $125 price target.
benzinga.com Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.- benzinga.com BTIG Maintains Buy on Oruka Therapeutics, Raises Price Target to $78 BTIG analyst Julian Harrison maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $73 to $78.
- benzinga.com HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $70 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $40 to $70.
- benzinga.com Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $125 Price Target Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $125 price target.
- benzinga.com Barclays Maintains Overweight on Oruka Therapeutics, Raises Price Target to $78 Barclays analyst Etzer Darout maintains Oruka Therapeutics (NASDAQ:ORKA) with a Overweight and raises the price target from $50 to $78.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday